文献速递血栓与止血

理解高龄如何驱动免疫性血小板减少症的决策与结局:一项纳入465例成人患者的单中心研究

Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients.
PubMed 文献 · Br J Haematol · 2018-11-08

该单中心研究分析1995至2017年诊断并随访至少12个月的465例成人免疫性血小板减少症(ITP)患者,比较年龄≥65岁(n=154)与年轻患者。两组一线、二线、三线治疗需求相当;老年患者严重出血更常见、起始治疗血小板计数更高、一线糖皮质激素剂量更低,后续更倾向温和免疫抑制治疗/血小板生成素受体激动剂;年轻患者更多接受利妥昔单抗和脾切除且完全缓解率更高。高龄是ITP诊断/治疗策略的重要驱动因素,导致不同的缓解率和并发症发生率。

要点

  • 老年ITP患者严重出血更常见,起始治疗时血小板计数更高,一线糖皮质激素剂量更低。
  • 年轻患者更多接受利妥昔单抗和脾切除,完全缓解率更高。
  • 高龄(P=0.01)和诊断时活动性出血(P=0.01)显著预测随访中≥2级出血。

核心结论

  • 高龄是ITP诊断和治疗策略的重要驱动因素,导致不同的缓解率和并发症发生率。

研究设计与样本

  • 单中心研究,纳入1995年至2017年诊断并在我院随访至少12个月的465例成人ITP患者,随访共4248患者年。

主要发现

  • 334例(71.8%)需要一线糖皮质激素治疗,其中85.3%在诊断后1年内开始。
  • 年轻与老年(年龄≥65岁,n=154)患者的一线、二线和三线治疗需求相当。
  • 老年患者更常出现严重出血,起始治疗时血小板计数更高,一线糖皮质激素剂量更低;此后更倾向接受温和的免疫抑制治疗/血小板生成素受体激动剂。
  • 年轻患者更常接受利妥昔单抗和脾切除,完全缓解率更高。
  • ≥2级并发症发生率:出血2.87/100患者年,感染1.55/100患者年,血栓0.66/100患者年。

关键数值与推荐

  • 高龄(P=0.01)和诊断时活动性出血(P=0.01)显著预测随访期间≥2级出血。
  • 高龄(P=0.01)、男性(P=0.01)和使用血小板生成素受体激动剂(P=0.02)与随时间推移更高的血栓概率显著相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We analysed the impact of older age on the management of immune thrombocytopenia (ITP) in 465 adult patients diagnosed between 1995 and 2017 and followed at our institution for a minimum of 12 months. Over a follow-up of 4248 patient-years, front-line corticosteroids therapy was required in 334 patients (71·8%), mainly (85·3%) within 1 year from diagnosis. Need for first-, second- and third-line therapy was comparable in younger and older (age ≥65 years, n = 154) patients. Older patients presented more frequently with severe haemorrhages, started therapy with a higher platelet count and received lower dose front-line corticosteroids; thereafter, they were preferentially treated with mild immunosuppressive therapies/thrombopoietin-receptor agonists. Conversely, younger patients were more frequently treated with rituximab and splenectomy, achieving higher rates of complete responses. Incidence rates of ≥grade 2 complications were: 2·87 (haemorrhages), 1·55 (infections) and 0·66 (thromboses) per 100 patient-years. Older age (P = 0·01) and active haemorrhages at diagnosis (P = 0·01) significantly predicted grade ≥2 haemorrhages during follow-up. Older age (P = 0·01), male gender (P = 0·01), and thrombopoietin receptor agonist use (P = 0·02) were significantly associated with a higher probability of thrombosis over time. Older age is a significant driver of diagnostic/therapeutic strategy in ITP resulting in different responses and complications rates.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Palandri F, Catani L, Auteri G, et al. Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients. Br J Haematol. 2018. PMID: 30408157. doi:10.1111/bjh.15668

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。